Carzelesin
Alternative Names: NSC D 619020; U 80244Latest Information Update: 28 Nov 2000
At a glance
- Originator Pharmacia Corporation
- Class Antineoplastics
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours